Zeria Pharmaceutical Co. Ltd. saw its profitability contract during the first nine months of the fiscal year, as stagnant revenue failed to offset rising costs. The Tokyo-listed drugmaker recorded ¥64.08 billion in revenue for the period ended Dec. 31, a slight decrease from the ¥64.77 billion generated in the same period a year earlier. This stalled growth filtered down to the operating level, where profit fell to ¥8.57 billion from ¥10.25 billion during the prior-year period.

Earnings and Margin Contraction

The company’s bottom line faced significant pressure, with net profit sliding to ¥5.55 billion compared to ¥8.23 billion in the previous year. According to the financial report, this resulted in earnings per share of ¥126.00, a notable decrease from the ¥186.63 reported in 2024. Pretax profit also saw a sharp decline, landing at ¥7.29 billion as the company managed a more difficult earnings environment.

Key performance metrics for the nine-month period included:

• Consolidated revenue of ¥64.08 billion
• Operating profit of ¥8.57 billion
• Net income of ¥5.55 billion

The results, which are based on Japanese accounting standards, highlight a challenging period for the firm as it navigated a flat sales environment and reduced earnings power across its core operations.